Market Failure? Lower Drug Prices Don't Improve Access In Rheumatoid Arthritis

 
• By Cathy Kelly

'Perverse incentives' guide US pricing for rheumatoid arthritis drugs, stakeholders say at policy roundtable convened by Institute for Clinical and Economic Review.

More from Pricing Debate

More from Market Access